Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX)
CUSIP: 00972G207
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Ordinary Shares, $0.000000005 par value
- Shares outstanding
- 94,284,567,045
- Total 13F shares
- 550,740
- Share change
- +246,442
- Total reported value
- $644,311
- Price per share
- $1.17
- Number of holders
- 15
- Value change
- +$288,311
- Number of buys
- 5
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 00972G207?
CUSIP 00972G207 identifies AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00972G207:
Top shareholders of AKTX - Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Palo Alto Investors LP |
13F
|
Company |
0%
|
146,024
|
$181,070 | — | 31 Mar 2025 | |
| Omnia Family Wealth, LLC |
13F
|
Company |
0%
|
87,628
|
$108,659 | — | 31 Mar 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0%
|
23,643
|
$29,317 | — | 31 Mar 2025 | |
| Cresset Asset Management, LLC |
13F
|
Company |
0%
|
18,408
|
$22,826 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0%
|
18,384
|
$22,796 | — | 31 Mar 2025 | |
| Accent Capital Management, LLC |
13F
|
Company |
0%
|
10,000
|
$12,400 | — | 31 Mar 2025 | |
| Torsten Hombeck |
3/4/5
|
CFO |
—
mixed-class rows
|
200,400
mixed-class rows
|
$468 | — | 20 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
150
|
$186 | — | 31 Mar 2025 | |
| Truvestments Capital LLC |
13F
|
Company |
0%
|
50
|
$62 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
6
|
$7 | — | 31 Mar 2025 | |
| Cornerstone Planning Group LLC |
13F
|
Company |
0%
|
5
|
$7 | — | 31 Mar 2025 | |
| Rachelle Suzanne Jacques |
3/4/5
|
Chief Executive Officer, Director |
—
class O/S missing
|
1,018,027,792
|
— | — | 26 Apr 2024 | |
| Wendy F. Dicicco |
3/4/5
|
Interim CFO |
—
class O/S missing
|
158,473,915
|
— | — | 01 May 2024 | |
| Donald A. Williams |
3/4/5
|
Director |
—
mixed-class rows
|
25,000,000
mixed-class rows
|
— | — | 28 Jun 2024 | |
| Michael Grissinger |
3/4/5
|
Director |
—
mixed-class rows
|
25,000,000
mixed-class rows
|
— | — | 28 Jun 2024 | |
| Mohamed Wa'El Ahmed Hashad |
3/4/5
|
Director |
—
class O/S missing
|
5,000,000
|
— | — | 28 Jun 2024 |
Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) as of Q2 2025
As of 30 Jun 2025,
Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
550,740 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, Palo Alto Investors LP, HighTower Advisors, LLC, Omnia Family Wealth, LLC, Cerity Partners LLC, Cresset Asset Management, LLC, RENAISSANCE TECHNOLOGIES LLC, Accent Capital Management, LLC, NewEdge Advisors, LLC, and EverSource Wealth Advisors, LLC.
This page lists
15
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
10
Q2 2025 holders
15
Holder diff
5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.